On June 2, 2026, Chongqing Precision Biotech presented Phase I clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting for its proprietary rapid-manufactured, IL-9–secreting CEACAM5-targeted CAR-T cell therapy administered via intraperitoneal infusion in patients with advanced colorectal cancer with peritoneal metastases (CRPM).

Colorectal cancer with peritoneal metastases (CRPM) remains one of the most challenging forms of advanced colorectal cancer and is associated with poor clinical outcomes. The efficacy of conventional systemic therapies is often limited by the blood–peritoneal barrier, particularly in patients who have progressed following multiple prior lines of treatment, where objective response rates (ORR) are typically below 5%. In 2024, researchers from Chongqing Precision Biotech and the First Affiliated Hospital, Zhejiang University School of Medicine, reported in Nature Cancer that intraperitoneal administration of CEA-targeted CAR-T cells achieved an ORR of 25% in patients with CRPM.

Data from the Phase I study demonstrated an ORR of 57.1% and a disease control rate (DCR) of 100% in heavily pretreated patients with advanced CRPM. Notably, the therapy achieved these outcomes using a CAR-T cell dose approximately one-tenth of that reported in conventional studies, while demonstrating a manageable safety profile.